PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) CEO Daniel Cohen says the company has completed significant groundwork to support multi-kilogram production for use in the final drug production of PD-001, its patented, oral version of cepharanthine, to treat responsive cancers and COVID-19.
Cohen told Proactive that PharmaDrug has engaged Genvion Corporation to complete stability testing and forced degradation studies in support of future investigational new drug (IND) filings to the US Food and Drug Administration (FDA).
He said the company will soon update the market on its psychedelic biotech research.